Silexion Therapeutics Corp
SLXN Nasdaq
SEC CIK 2022416
Follow Silexion Therapeutics
Weekly email: filings, results
EPS, diluted
$13.70
−98% vs same quarter last year
Operating cash flow
−$2.1M
+25.7% vs same quarter last year
Operating income
−$2.7M
+18.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$10.8M |
| FY24 | −$8.4M |
| FY23 | −$4.5M |
| FY22 | - |